Navigation Links
Biomira Shareholders Approve Move to U.S.
Date:12/4/2007

EDMONTON, Dec. 4 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) ("Biomira", the "Company") today announced that the Company's shareholders have approved a plan of arrangement under which the Company will move to the United States and change its name to Oncothyreon Inc. ("Oncothyreon"). The approval came at a special meeting of shareholders held today in Edmonton. Under the plan of arrangement, which remains subject to court approval, Oncothyreon will be the ultimate parent corporation of a successor corporation of the current Biomira and its subsidiaries. Upon the completion of the proposed arrangement, holders of common shares of Biomira will receive one-sixth of a share of common stock of Oncothyreon in exchange for each common share of Biomira. Oncothyreon intends to establish its headquarters in or near Seattle, Washington.

"We are very pleased to have received the strong support of our shareholders for our relocation and the revision of our capital structure," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "The management and Board of Directors of Biomira believe these steps are essential elements of our vision to create long term sustainable value for our shareholders, and we are gratified that our shareholders have agreed. We will continue to work to advance our exciting pipeline of anti-cancer product candidates to justify the confidence in our future represented by this vote."

Implementation of the plan of arrangement remains subject to receipt of a Final Order from the Alberta Court of Queen's Bench. Assuming receipt of court approval, Biomira intends to file articles of amendment to effect the plan of arrangement on or about December 10, 2007, and to commence trading as Oncothyreon on the Nasdaq National Market under the symbol "ONTY" and on the Toronto Stock Exchange under the symbol "ONY" shortly thereafter. Letters of transmittal are expected to be mailed to registered shareholders commencing December 5, 2007.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward Looking Statements

In order to provide Biomira's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements relating to court approval of the proposed reincorporation of Biomira from Canada to the United States, the timing and benefits thereof and future clinical development plans. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to the proposed reincorporation transaction, Biomira's business and the general economic environment. Many of these risks and uncertainties are beyond Biomira's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the completion and benefits of the proposed arrangement and reincorporation; future clinical development plans; and the other risks and uncertainties described in the reports and other documents, including the registration statement on Form S-4, filed by either Biomira Inc. or Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Biomira believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Biomira and Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in the amended registration statement on Form S-4 filed by Oncothyreon Inc. with the SEC and on SEDAR. Biomira and Oncothyreon are under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Biomira Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomira Announces Plan to Reincorporate in the United States
2. Biomira announces plan to change name to Oncothyreon
3. Biomira to present at the BIO InvestorForum 2007
4. Biomira Inc. receives Nasdaq delisting notification
5. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
8. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
9. Pharmos Issues Letter to Shareholders
10. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
11. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... STANFORD, Calif. , Aug. 15, 2017 After spending ... resources and support with crowdsourced data collection, GeneFo now offers this ... interested in aligning and amplifying support, adherence, and data collection vis ... with medical foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is pleased ... analytical and scientific instruments. This year’s symposium, organized by the Pittcon 2018 program ... for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high throughput ...
(Date:8/15/2017)... ... ... The Conference Forum and The Trout Group will ... upcoming panels and events. The partnership culminates with the 4th Annual IO360° summit ... City. , “With our experience in producing the Immuno-Oncology 360° NYC event and The ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):